Clinical Trial Update: Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III) [Phase 3]

View source ↗

Summary

Phase 3 trial update on the immunogenicity and safety of Vi-DT typhoid conjugate vaccine completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Typhoid Fever

Drugs mentioned

• Vi-DT (Diphtheria Toxoid Typhoid Conjugate Vaccine) (Vi-DT)

Snippet

Sponsor: PT Bio Farma | Conditions: Safety Issues, Immunogenicity | Phase 3 | Status: COMPLETED